Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

A Phase II Study of Lenalidomide Plus Rituximab in Patients with Newly Diagnosed Follicular Lymphoma: An Interim Analysis

Zhong Zheng, Li Wang, MD PhD, Shu Cheng, Pengpeng Xu, Weili Zhao, MD PhD

Blood (2019) 134 (Supplement_1): 3984.

https://doi.org/10.1182/blood-2019-126667

Published: 2019

Journal Articles

Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Kami J. Maddocks, MD, Farrukh T. Awan, MD MS, Ying Huang, MA, MS, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MD MS, Samantha Jaglowski, MD MPH, Basem M. William, MRCP, MD, Kristie A. Blum, MD, Beth A. Christian, MD

Blood (2018) 132 (Supplement 1): 4185.

https://doi.org/10.1182/blood-2018-99-117172

Published: 2018

Journal Articles

AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 445.

https://doi.org/10.1182/blood-2018-99-110861

Published: 2018

Journal Articles

Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Final Results from a Phase 2 Multicenter Study

Blood (2018) 132 (Supplement 1): 2896.

https://doi.org/10.1182/blood-2018-99-117244

Published: 2018

Journal Articles

Recurrent Gene Mutations and Clinical Outcome in the Context of Lenalidomide Treatment of Relapsed/Refractory CLL — Results from Multicenter Phase II Trial CLL-009

Veronika Opatrna, MD, Eugen Tausch, MD, Graeme Fraser, MD, Anne-Sophie Michallet, MD PhD, Peter Hillmen, MBChB, PhD, Jan Dürig, MD, Matt Kalaycio, MD, John G. Gribben, MDDSc FMedSci, Thomas J. Kipps, MD, Brendan Purse, Jennie Zhang, Sabine De Bedout, Asher A. Chanan-Khan, MD, Michael J. Hallek, MD, Clemens-Martin Wendtner, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 4311.

https://doi.org/10.1182/blood.V130.Suppl_1.4311.4311

Published: 2017

Journal Articles

Efficacy and Safety of First-Line Therapy with Chlorambucil, Rituximab and Individualized Dose Lenalidomide in FCR-Unfit Patients with Advanced Chronic Lymphocytic Leukemia (CLL): A Phase I/II HOVON Trial

Blood (2017) 130 (Supplement 1): 4328.

https://doi.org/10.1182/blood.V130.Suppl_1.4328.4328

Published: 2017

Journal Articles

Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study

Blood (2016) 128 (22): 181.

https://doi.org/10.1182/blood.V128.22.181.181

Published: 2016

Journal Articles

A Phase II Study of the Combination of Lenalidomide and Rituximab in Patients with Treatment-NaïVe and Relapsed Chronic Lymphocytic Leukemia

Paolo Strati, MD, Philip A Thompson, MBBS, Michael Keating, MBBS, Christina Hinojosa, Diana Rodriguez, Xuemei Wang, MS, Naval G. Daver, MD, Nitin Jain, MD, Jan A. Burger, MD PhD, Zeev Estrov, MD, William G. Wierda, MD PhD, Hagop M. Kantarjian, MD, Susan Obrien, MD BA, Alessandra Ferrajoli, MD

Blood (2016) 128 (22): 4389.

https://doi.org/10.1182/blood.V128.22.4389.4389

Published: 2016

Journal Articles

Updated Results of a Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

Beth A Christian, MD, John G. Kuruvilla, MD, Sonali M. Smith, MD, Pierluigi Porcu, MD, Kami J. Maddocks, MD, Amy S. Ruppert, MAS, John C Byrd, MD, Michael R. Grever, MD, Kristie A. Blum, MD

Blood (2015) 126 (23): 3983.

https://doi.org/10.1182/blood.V126.23.3983.3983

Published: 2015

Journal Articles

A Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

Beth Christian, MD, John Kuruvilla, MD, Sonali Smith, MD, Pierluigi Porcu, MD, Amy S. Ruppert, MAS, John C. Byrd, MD, Michael R. Grever, MD, Kristie A. Blum, MD

Blood (2014) 124 (21): 4476.

https://doi.org/10.1182/blood.V124.21.4476.4476

Published: 2014

Journal Articles

Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator’s Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study

Marek Trneny, Thierry Lamy, Jan Walewski, Wojciech Jurczak, David Belada, MD, Jiri Mayer, Prof., MD PhD, John Radford, Julia Alexeeva, Dzhelil Osmanov, Tsvetan Biyukov, Meera Patturajan, Marie-Laure Casadebaig Bravo, Luca Arcaini

Blood (2014) 124 (21): 626.

https://doi.org/10.1182/blood.V124.21.626.626

Published: 2014

Journal Articles

A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Daniel A. Pollyea, MD MS, Steven Coutre, MD, Lia Gore, Nichole Adler, RN, BSN, Pamela Harris, MD, Mitch A. Phelps, PhD, Amy J. Johnson, PhD, YongHua Ling, Hao Li, Jonathan A Gutman, MD, John C. Byrd, MD

Blood (2014) 124 (21): 1987.

https://doi.org/10.1182/blood.V124.21.1987.1987

Published: 2014

Journal Articles

Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome

Christiane Querfeld, Steven T. Rosen, Joan Guitart, Madeleine Duvic, Youn H. Kim, Stephen W. Dusza, Timothy M. Kuzel

Blood (2014) 123 (8): 1159–1166.

https://doi.org/10.1182/blood-2013-09-525915

Published: 2014

Journal Articles

Lenalidomide and Rituximab For The Treatment Of Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results Of Planned Interim Analysis

Michael Y. Choi, MD, Januario E. Castro, M.D., Sheila Hoff, RN, Hongying Li, PhD, Laura Rassenti, PhD, Danelle F. James, M.D., M.A.S., Karen Messer, PhD, Thomas J. Kipps, MD, PhD

Blood (2013) 122 (21): 5299.

https://doi.org/10.1182/blood.V122.21.5299.5299

Published: 2013

Journal Articles

A Phase 1/2 Study Of The Safety and Activity Of Escalating Doses Of Lenalidomide Plus Rituximab For Patients With Refractory Or Relapsed Chronic Lymphocytic Leukemia (LLC-Lenar-08)

Jose Francisco Tomas, MD, PhD, Marcos González, MD, Pilar Giraldo, MD PhD, Mª José Terol, Jose Antonio Pérez Simón, MD, PhD, Raquel de Oña, MD

Blood (2013) 122 (21): 5304.

https://doi.org/10.1182/blood.V122.21.5304.5304

Published: 2013

Journal Articles

Phase II Multicenter Study of the Safety and Efficacy of Single-Agent Lenalidomide in Subjects with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Follow-up Analysis of the NHL-003 Study.

Pier Luigi Zinzani, MD, Julie M Vose, MD, MBA, Myron S. Czuczman, MD, Craig Reeder, MD, Corinne Haioun, MD, Jonathan Polikoff, MD, Herve Tilly, Dennis Pietronigro, Annette Ervin-Haynes, Ju Li, Thomas E. Witzig, MD

Blood (2012) 120 (21): 2738.

https://doi.org/10.1182/blood.V120.21.2738.2738

Published: 2012

Journal Articles

Combination of Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial

Alessandra Ferrajoli, M.D., Lorenzo Falchi, MD, Susan O'Brien, MD, William Wierda, MD, PhD, Stefan Faderl, MD, Susan C. Smith, BS, Ana B. Ayala, ADN, Hagop M. Kantarjian, MD, Michael J. Keating, MD

Blood (2012) 120 (21): 720.

https://doi.org/10.1182/blood.V120.21.720.720

Published: 2012

Journal Articles

Phase 2 Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia

Luciano J Costa, MD, PhD, Suzanne Fanning, DO, Joseph Stephenson, MD, Lawrence Afrin, MD, Tricia Bentz, Shanta Salzer, Rachel Whirley, Carlyn Sander, Robert K Stuart, MD

Blood (2012) 120 (21): 3933.

https://doi.org/10.1182/blood.V120.21.3933.3933

Published: 2012

Journal Articles

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 “EMERGE” Study

Andre Goy, MD, Rajni Sinha, MD, MRCP, Michael E. Williams, M.D., Sevgi Kalayoglu Besisik, Johannes Drach, Radhakrishnan Ramchandren, MD, Michael J. Robertson, MD, Irit Avivi, MD, Jacob M. Rowe, Raoul Herbrecht, MD, Achiel Van Hoof, Miklos Egyed, MD, PhD, Lei Zhang, MD, Sherri Cicero, Tommy Fu, Thomas E. Witzig, MD

Blood (2012) 120 (21): 905.

https://doi.org/10.1182/blood.V120.21.905.905

Published: 2012

Journal Articles

Lenalidomide Consolidation Appears to Prolong Time to Retreatment After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL,

Tait D. Shanafelt, MD, Han Tun, MD, Curtis A. Hanson, MD, Clive S. Zent, MD, Jose F. Leis, MD, PhD, Timothy G Call, MD, Betsy R. LaPlant, Deborah Bowen, EmilyS S Pavey, Diane F. Jelinek, Ph.D., Neil Kay, MD

Blood (2011) 118 (21): 3899.

https://doi.org/10.1182/blood.V118.21.3899.3899

Published: 2011

NARROW

A Phase II Study of Lenalidomide Plus Rituximab in Patients with Newly Diagnosed Follicular Lymphoma: An Interim Analysis

Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Final Results from a Phase 2 Multicenter Study

Recurrent Gene Mutations and Clinical Outcome in the Context of Lenalidomide Treatment of Relapsed/Refractory CLL — Results from Multicenter Phase II Trial CLL-009

Efficacy and Safety of First-Line Therapy with Chlorambucil, Rituximab and Individualized Dose Lenalidomide in FCR-Unfit Patients with Advanced Chronic Lymphocytic Leukemia (CLL): A Phase I/II HOVON Trial

Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study

A Phase II Study of the Combination of Lenalidomide and Rituximab in Patients with Treatment-NaïVe and Relapsed Chronic Lymphocytic Leukemia

Updated Results of a Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

A Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator’s Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study

A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome

Lenalidomide and Rituximab For The Treatment Of Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results Of Planned Interim Analysis

A Phase 1/2 Study Of The Safety and Activity Of Escalating Doses Of Lenalidomide Plus Rituximab For Patients With Refractory Or Relapsed Chronic Lymphocytic Leukemia (LLC-Lenar-08)

Phase II Multicenter Study of the Safety and Efficacy of Single-Agent Lenalidomide in Subjects with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Follow-up Analysis of the NHL-003 Study.

Combination of Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial

Phase 2 Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 “EMERGE” Study

Lenalidomide Consolidation Appears to Prolong Time to Retreatment After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only